{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"47.0","value":"175"},{"groupId":"OG001","spread":"55.4","value":"174"}]}],"title":"Cycle 1, Day 1 (LDAC Alone)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"32.1","value":"166"},{"groupId":"OG001","spread":"62.3","value":"175"}]}],"title":"Cycle 1, Day 10 (LDAC with Venetoclax)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"description":"The highest concentration that a drug achieves in the blood after administration in a dosing interval.","dispersionType":"Standard Deviation","groups":[{"description":"Venetoclax was administered orally once daily (QD) on Days 2 through 28 of Cycle 1. Dosing started at 50 mg (Day 2) and increased up to 600 mg by Day 6. Beginning with Cycle 2, 600 mg venetoclax was administered Days 1 through 28 of each 28-day cycle. Participants also received low-dose cytarabine (LDAC; 20 mg/m²) administered by subcutaneous injection once daily on Days 1 to 10 of each cycle.","id":"OG000","title":"Phase 1: 600 mg Venetoclax + LDAC"},{"description":"Venetoclax was administered orally once daily (QD) on Days 2 through 28 of Cycle 1. Dosing started at 100 mg (Day 2) and increased up to 800 mg by Day 6. Beginning with Cycle 2, 800 mg venetoclax was administered Days 1 through 28 of each 28-day cycle. Participants also received LDAC (20 mg/m²) administered by subcutaneous injection once daily on Days 1 to 10 of each cycle.","id":"OG001","title":"Phase 1: 800 mg Venetoclax + LDAC"}],"paramType":"MEAN","populationDescription":"Participants enrolled in Phase 1 who had at least one dose of cytarabine and had at least one reported PK sample concentration.","reportingStatus":"POSTED","timeFrame":"Cycle 1, Day 1 and Day 10 at pre-dose and at 15 and 30 minutes and 1, 3, 6 hours post-dose.","title":"Phase 1: Maximum Observed Plasma Concentration (Cmax) of Cytarabine","type":"PRIMARY","unitOfMeasure":"ng/mL"}